Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AxIn study
2024-511397-70-00Phase 2Authorised
- Sponsor
- Consorzio Oncotech
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of axitinib in renal cell carcinoma (RCC) (3 arms), sponsored by Consorzio Oncotech. Primary endpoint: Overall response rate. Planned start Mar 2024; status: authorised.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-511397-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511397-70-00.